PROM1 and colorectal cancer: CD133 levels in colorectal cancers have been found to increase in a radiation dose-dependent manner [26]; an elevated CD133 level has been implicated in the development of resistance to chemoradiotherapy [27], and has been linked to poor prognosis in GI cancers [28].